Outlook Therapeutics, Inc. 8-K

What Happened
On April 21, 2026, Outlook Therapeutics, Inc. announced (via a press release attached to a Form 8-K) that it conducted the requested Federal Dispute Resolution meeting with the FDA’s Office of New Drugs. The meeting was held to appeal a Complete Response Letter (CRL) dated December 30, 2025 concerning the company’s biologics license application (BLA) resubmission for ONS-5010, an investigational ophthalmic formulation of bevacizumab being developed to treat wet age-related macular degeneration (wet AMD).

Key Details

• April 21, 2026: Company issued press release and filed Form 8-K (Item 8.01) reporting the meeting.
• December 30, 2025: Date of the CRL for the ONS-5010 BLA resubmission.
• Product: ONS-5010 — investigational ophthalmic bevacizumab for treatment of wet AMD.
• Press release is attached as Exhibit 99.1 to the Form 8-K.

Why It Matters
This filing reports that Outlook is pursuing formal dispute resolution with the FDA, a step that may affect the regulatory path and timing for potential approval of ONS-5010. The 8-K does not disclose the outcome or any revised timeline; investors should monitor future company filings and FDA communications for results of the appeal and any implications for development milestones, commercialization prospects, or valuation.